ArticleBMJ open ophthalmology2020

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series.

Muna Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.